IP Verse

Mylan Laboratories competitive analysis

Latest publications and patents of Mylan Laboratories New

Explore the latest publications and patents granted to Mylan Laboratories, showcasing their recent innovations and technological advancements.

Last updated on: Sep 23, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Mylan Laboratories

EP2299989
Jan 2, 2019Stabilized Transdermal Drug Delivery SystemOpposition Rejected
EP2682388
Jan 10, 2018Novel Polymorphic Forms Of Perindopril (L)-Arginine And Process For The Preparation ThereofRevoked

Latest patents of Mylan Laboratories opposed by its competitors

Explore Mylan Laboratories's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 25, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2299989
Jan 2, 2019Stabilized Transdermal Drug Delivery System1
EP2682388
Jan 10, 2018Novel Polymorphic Forms Of Perindopril (L)-Arginine And Process For The Preparation Thereof2

Latest PTAB cases involving Mylan Laboratories

Discover the latest PTAB cases involving Mylan Laboratories, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 29, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Mylan Laboratories

IPR2020-00440Feb 7, 2020MYLAN LABORATORIESJANSSEN PHARMACEUTICAInstitution Denied
IPR2016-00712Mar 15, 2016MYLAN LABORATORIESAVENTIS PHARMAFinal Written Decision
IPR2016-00627Feb 17, 2016MYLAN LABORATORIESAVENTIS PHARMAInstitution Denied

Peer Comparison New

IP litigation analysis comparing Mylan Laboratories with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 25, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
MYLAN LABORATORIES - 33 - Aggressive
AVENTIS PHARMA - 23 - 3Non-Active
HOEFER & PARTNER PATENTANWALTE MBB13 - - - Highly Aggressive
JANSSEN PHARMACEUTICA154 - 1Defensive